4-FMC Stats & Data

Reasoning for harm‑reduction additions (with sources): 1) Mislabeling risk is high: both 3‑FMC and 4‑FMC have been sold as “flephedrone”; this explains divergent reports and mandates allergy testing and lab checking when possible. Bluelight threads explicitly discuss the 3‑FMC/4‑FMC confusion; EMCDDA’s cathinone profile lists 4‑FMC as flephedrone and notes NPS are often mis‑sold. 2) Oral vs insufflated risks: user timelines support short, stacked duration with a harsher crash when snorted; several reports describe painful, irritating drips and long tails after repeat lines. Favor oral to reduce nasal damage and compulsive re‑lining. 3) MAOI combos are dangerous with stimulants/MDMA due to hypertensive crisis and serotonin toxicity; this general rule applies to cathinones as mixed monoamine agents. 4) Tramadol and bupropion lower the seizure threshold; both increase seizure risk when combined with stimulants. Avoid. 5) General stimulant harm reduction applies: overheating and hypertension are risks; stay cool, avoid hot environments, plan rest; do not mix multiple stimulants. 6) Injection/rectal use increases harm and has been linked to outbreaks (HIV/HCV) with cathinones in Europe; avoid injecting and share no equipment. 7) Set dosing boundaries to prevent binges: pre‑measure single dose plus at most one booster; lock away remainder; use a milligram scale; avoid multi‑day runs to reduce comedown intensity and sleep deprivation. 8) Hydration: sip small amounts of electrolyte fluids regularly; avoid overhydration; take cooling breaks. 9) Post‑use care: magnesium for bruxism, gentle nutrition, sleep hygiene; avoid alcohol and strong stimulants on the comedown. 10) Space uses generously: at least 2–4 weeks between sessions to let tolerance and mood normalize. 11) Drug checking: use reagents and, where available, lab drug checking services; branded “legal highs” may contain other cathinones (e.g., MDPV) with very different dose ranges. 12) If chest pain, severe agitation, hyperthermia, or persistent tachycardia occurs, seek urgent care and disclose stimulant use. Sources are cited below. Overall toxicity data for 4‑FMC in humans are sparse; guidance extrapolates from related cathinones and HR best practice.